A Phase 1, Open-Label, Single Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PD 0332334 In Subjects With Various Degrees Of Renal Function.
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2010
At a glance
- Drugs Imagabalin (Primary)
- Indications Anxiety disorders
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Pfizer
- 25 Mar 2009 Actual end date changed from Mar 2009 to Feb 2009 as reported by ClinicalTrials.gov.
- 03 Mar 2009 Planned number of patients changed from 32 to 16 as reported by ClinicalTrials.gov.
- 03 Mar 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.